Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4917523 Phase 2 Trial in Fragile X Syndrome
2011-004349-42Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Fragile X syndrome (FXS) comparing RO4917523 with Placebo (2 arms). Primary endpoint: Change in ADAMS total score. Started Apr 2012; status: completed.
02
Drugs
basimglurant
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on 2011-004349-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004349-42.